Arrowhead Pharmaceuticals (ARWR) is back in focus after Ken Fisher’s fund increased its holdings and management spotlighted upcoming Phase III SHASTA-3 and SHASTA-4 readouts for plozasiran, which has been flagged as a multibillion dollar commercial opportunity.

At a share price of US$56.71, Arrowhead has had a 1 month share price return of 11.14% and a year to date share price decline of 16.34%, set against a very large 1 year total shareholder return of about 3.7x. This suggests that long term momentum contrasts with more cautious recent sentiment as investors weigh Fisher’s increased stake and the upcoming SHASTA-3 and SHASTA-4 readouts.

If you are looking for other high potential biotech names tied to similar themes, it could be worth scanning for RNA focused healthcare names using our 35 healthcare AI stocks

With Arrowhead trading at US$56.71, an indicated intrinsic value gap of about 61% and a roughly 43% discount to analyst targets raise a key question: is this genuine mispricing, or is the market already factoring in future growth?

Most Popular Narrative: 11.5% Undervalued

With Arrowhead closing at $56.71 against a most followed fair value estimate of $64.08, the current price sits below that narrative benchmark and puts extra focus on what is being assumed about revenue, margins and risk.

Arrowhead's advancing late-stage clinical pipeline, especially the expected launch of plozasiran for FCS and SHTG, plus pivotal studies for three other RNAi therapies targeting major unmet needs, positions the company to capitalize on rising demand for treatments driven by an aging population and increasing prevalence of chronic and genetic diseases, which could significantly accelerate revenue growth as approvals and launches materialize.

Curious what kind of revenue path and margin profile sit behind that fair value, and how a very high future earnings multiple is being justified? The narrative leans heavily on a detailed set of assumptions around pipeline timing, partnership economics and long term profitability that go well beyond a simple P/E snapshot.

Result: Fair Value of $64.08 (UNDERVALUED)

However, this hinges on milestones converting as planned and SHASTA readouts landing cleanly, since partner delays or weaker data could quickly undercut that undervalued narrative.

Another View On Valuation

While the narrative fair value points to Arrowhead being undervalued, the current P/E of 39.3x is roughly double both the US Biotechs industry at 20x and the peer average of 19.4x, and also well above a fair ratio of 19.9x. This suggests meaningful valuation risk if sentiment cools.

That kind of premium multiple can persist for a time. However, it also raises the question of how much future success is already embedded in the price and how much room is left if expectations slip even slightly, or if peers start to close the gap.

Next Steps

Given all this mixed sentiment around price, growth expectations and risk, it makes sense to move quickly and review the numbers yourself. To understand what is driving optimism, take a closer look at the 2 key rewards

Looking for more investment ideas?

If Arrowhead has your attention, do not stop here. Use the tools available to quickly surface other opportunities that could fit your goals and risk tolerance.

• Target potential value opportunities by scanning companies that appear mispriced on quality and fundamentals with the 49 high quality undervalued stocks.
• Prioritize resilience by focusing on businesses that score well on financial strength using the solid balance sheet and fundamentals stocks screener (40 results).
• Hunt for lesser known prospects with solid fundamentals by checking the screener containing 26 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.